Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial - Soria, J C; Felip, E; Cobo, M (Lancet Oncol, 2015)
et al.